Compare Freeport-McMoRan Inc (FCX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Recursion Pharmaceuticals Inc — how do they compare? Freeport-McMoRan Inc trades at $68.92 (market cap $98.71B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Freeport-McMoRan Inc is far larger — about 55.5× Recursion Pharmaceuticals Inc's market cap, and Freeport-McMoRan Inc pays a 0.85% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| FCX | RXRX | |
|---|---|---|
Market Cap | $98.71B | $1.78B |
Sector | Basic Materials | Health |
52-Week High | $71.73 | $6.79 |
52-Week Low | $35.34 | $2.84 |
Enterprise Value | $104.99B | $1.30B |
Dividend Yield | 0.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $69.62, up 2.1% today, with a bullish technical signal from moving averages but overbought RSI near 86. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $0.68 above the $0.60 forecast. Revenue reached $25.92B in 2025, with net income margin improving to 8.5%. Recent news highlights progress at the Grasberg mine and strong copper prices supporting operations.
Outlook is positive with a consensus price target of $73.85, implying 6% upside, backed by 61% analyst buy ratings. Risks include reliance on commodity cycles and potential volatility from economic shifts. The company's solid cash flow and debt reduction trend provide stability, but investors should monitor copper market dynamics for sustained growth.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
